Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Kenneth Galbraith
|
| gptkbp:collaboratedWith |
gptkb:Pfizer
gptkb:GSK gptkb:Johnson_&_Johnson gptkb:Merck gptkb:Daiichi_Sankyo Iconic Therapeutics |
| gptkbp:country |
gptkb:Canada
|
| gptkbp:focusesOn |
oncology
protein therapeutics antibody therapeutics |
| gptkbp:founded |
2003
|
| gptkbp:founder |
gptkb:Ali_Tehrani
|
| gptkbp:headquartersLocation |
gptkb:Vancouver,_British_Columbia,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zymeworks Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
gptkb:Toronto_Stock_Exchange |
| gptkbp:notableProduct |
zanidatamab
|
| gptkbp:numberOfEmployees |
approximately 300
|
| gptkbp:platform |
AlbuCORE
Azymetric EFECT ProTECT |
| gptkbp:servesArea |
worldwide
|
| gptkbp:specializesIn |
antibody-drug conjugates
bispecific antibodies |
| gptkbp:subsidiary |
Zymeworks BC Inc.
|
| gptkbp:tradedOn |
NASDAQ: ZYME
TSX: ZYME |
| gptkbp:website |
https://www.zymeworks.com/
|
| gptkbp:bfsParent |
gptkb:Zymeworks_(regional_office)
gptkb:ZYM |
| gptkbp:bfsLayer |
7
|